Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for NCI-H292 Cells (Lung Carcinoma Cells, CRL-1848)
- Two component formulation enhances lipid mediated transfection efficiency
- Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
- Kit includes Transfection Enhancer reagent and recommended transfection protocol
- Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
- Reproducible transfection results
- Works well for standard reverse transfection and high-throughput applications
- Download NCI-H292 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for NCI-H292 cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 93% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NCI-H292 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NCI-H292 Cell Line:
NCI-H292 cells are sensitive for many different viruses, including herpes simplex virus, measles virus, mumps as well as some strains of influenza virus type A. This makes them an excellent substitute for MK cells with regard to laboratory safety, paramyxovirus isolation, and ease of use, according to the Journal of Clinical Microbiology (Jun 1993, Vol.31, pp. 1504–1510) The NCI-H292 tumorigenic cell line is derived from a lymph node metastasis lung cells of a 32-year-old female with mucoepidermoid pulmonary carcinoma and exhibits epithelial morphology. NCI-H292 cells have been negatively tested for L-DOPA decarboxylase and display the same mucoepidermoid characteristics as normal (non-cancerous) cells do. NCI-H292 cells susceptible to the Hepatitis B virus, making them valuable tools for biomedical research. This cell line is used as in vitro model in a variety of molecular and cell biology research related to lung cancer. Altogen Biosystems manufactures high-efficiency transfection reagent kits for this cell line.
NCI-H292 cell line mutations:
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the NCI-H292 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).
Figure 2. Protein expression of GAPDH in NCI-H292 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into NCI-H292 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, electroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6858)
- 1.5 ml (Catalog #6859)
- 1.5 ml CRISPR (Catalog #2179)
- 8.0 ml (Catalog #7013)